NAD+ Iontophoresis Patches: Evidence, Delivery, and What We Know in 2026
The phrase “NAD+ patch” can describe two very different technologies. Some products are passive adhesive patches intended to release ingredients onto the skin without electrical assistance. Others use iontophoresis, a low-level electrical current designed to assist the movement of suitable ionic substances across the skin.
That difference matters when evaluating claims about transdermal NAD+ delivery.
Iontophoresis is an established drug-delivery technology, but research specifically evaluating NAD+ delivered by iontophoresis remains limited. A published 2024 human pilot study did use NAD+ with an IontoPatch STAT, providing important evidence that this approach has been tested clinically. However, the study was small, uncontrolled, combined NAD+ with low-dose naltrexone, and did not establish that NAD+ iontophoresis alone produces the reported clinical effects.
This guide separates what is known about the delivery technology from what has—and has not—been demonstrated specifically for NAD+.
Quick Answer: Has NAD+ Iontophoresis Been Studied in Humans?
Yes, but the evidence is still preliminary.
A 2024 peer-reviewed pilot study followed 36 people with persistent moderate-to-severe fatigue after COVID-19 who received low-dose naltrexone plus NAD+ administered with an iontophoresis patch for 12 weeks. Participants reported improvements in fatigue and quality-of-life measures, and 52% were categorized as responders. The researchers nevertheless emphasized that larger randomized controlled trials are needed.
Importantly, the study does not establish that:
- NAD+ alone caused the improvements.
- Every NAD+ formulation will behave similarly during iontophoresis.
- A particular NAD+ blood or tissue concentration is achieved with an iontophoresis patch.
- NAD+ iontophoresis is superior to IV, injectable, oral, or other NAD-related approaches.
- The results apply to conditions other than the population that was studied.
For clinicians and patients evaluating this technology, that distinction is more useful than treating all “NAD patches” as interchangeable.
Passive NAD+ Patch vs. NAD+ Iontophoresis Patch
Intact skin is intentionally difficult for many substances to cross. The outer stratum corneum presents an especially substantial barrier to molecules that are relatively large, hydrophilic, or ionized. Iontophoresis is one method used to assist transdermal transport rather than relying solely on passive diffusion.
| Feature | Passive NAD+ Patch | Iontophoresis NAD+ Patch |
|---|---|---|
| Electrical current | No | Yes, low-level current |
| Primary delivery mechanism | Passive diffusion | Electrically assisted transport |
| Designed to enhance movement of ionic compounds | No active mechanism | Yes, when formulation and polarity are appropriate |
| Evidence that the technology can enhance transdermal delivery | Depends on formulation | Well established for appropriate ionized drugs and formulations |
| NAD+-specific human evidence | Limited | A small 2024 human pilot study has been published. |
| Can systemic NAD+ exposure be assumed? | No | No |
| Is every NAD+ formulation interchangeable? | No | No |
This distinction is important for search terms such as “NAD patch,” “transdermal NAD+,” and “NAD+ iontophoresis patch.” A passive supplement-style patch should not automatically be treated as equivalent to an electrically powered iontophoresis device.
What Is NAD+?
Nicotinamide adenine dinucleotide (NAD+) is a naturally occurring coenzyme involved in cellular energy metabolism, oxidation-reduction reactions, DNA-related processes, and numerous enzyme systems.
Interest in NAD+ has expanded alongside research involving NAD+ itself and NAD-related compounds such as nicotinamide riboside and nicotinamide mononucleotide.
However, the biological importance of NAD+ does not by itself demonstrate that any particular supplement or delivery route produces a clinical benefit. Questions involving oral NAD-related products, injections, intravenous administration, passive patches, and iontophoresis need to be evaluated separately because each method has different pharmacologic and delivery characteristics.
How Does Iontophoresis Change Transdermal Delivery?
Iontophoresis applies a small direct electrical current across the skin. For appropriately formulated ionic substances, electrical forces can assist transport through the skin rather than leaving delivery entirely dependent on passive diffusion.
The amount and direction of transport can be influenced by variables including:
- Electrical charge of the active species
- Drug concentration
- Formulation and counterions
- Solution pH
- Current
- Treatment duration
- Skin resistance
- Electrode design and surface area
For a broader explanation of the technology, see our iontophoresis treatment and product resources.
A Critical Point About the “+” in NAD+
The plus sign in NAD+ should not be interpreted as a universal instruction to place every NAD formulation under a positive iontophoresis electrode. The behavior of a prepared solution depends on the actual pharmaceutical formulation and treatment protocol.
We address that subject separately in the NAD+ polarity and iontophoresis guide so that the chemistry does not need to be duplicated here.
What Did the Published NAD+ Iontophoresis Study Actually Test?
The most directly relevant published human evidence identified for NAD+ iontophoresis is a 2024 study in Brain, Behavior, & Immunity—Health.
The study involved people experiencing persistent fatigue after COVID-19 and tested two interventions together: low-dose naltrexone and NAD+ delivered through iontophoresis.
| Study Detail | What Was Reported |
|---|---|
| Participants receiving treatment | 36 |
| Study duration | 12 weeks |
| Low-dose naltrexone | Up to 4.5 mg/day |
| NAD+ concentration | 400 mg/mL |
| Solution volume used in protocol | 1 mL |
| Iontophoresis device | IontoPatch STAT |
| Patch schedule | Once weekly |
| Approximate wear time | 4–6 hours |
| Primary assessments | Self-reported quality of life and fatigue |
| Responders after 12 weeks | 52% |
| Patch-related finding | Mild, short-lived skin irritation reported in 25% of participants |
The study reported improvement from baseline in both SF-36 quality-of-life scores and Chalder fatigue scores. Those findings are scientifically interesting, but the study design substantially limits what can be concluded from them.
Why the Findings Should Be Interpreted Carefully
The trial ultimately became an open-label, single-arm observational study rather than a completed randomized placebo-controlled trial. Participants knew they were receiving treatment, and there was no concurrent untreated or placebo comparison group in the final analysis.
More importantly, participants received both NAD+ and low-dose naltrexone.
That means the research cannot determine whether an observed change resulted from:
| Possible Factor | Can the Study Separate It? |
|---|---|
| NAD+ iontophoresis | No |
| Low-dose naltrexone | No |
| Combination of the two | Not from placebo or natural recovery |
| Placebo or expectation effects | No |
| Natural change over time | No |
| Other uncontrolled variables | No |
The authors themselves concluded that larger randomized controlled trials are necessary to confirm the findings.
The Study Protocol Is Not a Universal NAD+ Treatment Protocol
The specific concentration, volume, electrode assignment, wear time, and frequency reported in this study describe what investigators used in that particular research protocol. They should not be interpreted as universal instructions for administering NAD+.
Medication selection, concentration, polarity, dose, treatment schedule, and suitability for a particular patient should be established by an appropriately licensed healthcare professional and the dispensing pharmacy when applicable.
What Has Not Yet Been Established About NAD+ Iontophoresis?
The present literature leaves several clinically important questions unanswered.
| Research Question | Current Evidence |
|---|---|
| Can iontophoresis enhance transport of appropriate ionic compounds through skin? | Established principle |
| Has NAD+ been administered using iontophoresis in humans? | Yes. |
| Has a controlled trial isolated the effect of NAD+ iontophoresis alone? | Not established |
| Has predictable systemic NAD+ bioavailability from the patch been demonstrated? | Not established |
| Has an optimal NAD+ iontophoresis dose been established? | Not established |
| Has an optimal treatment frequency been established? | Not established |
| Has NAD+ iontophoresis been proven superior to IV NAD+? | No head-to-head evidence identified |
| Has it been proven superior to oral NAD-related products? | No head-to-head evidence identified |
| Are different iontophoresis patch systems interchangeable for NAD+? | Not established |
This is why claims such as “high bioavailability,” “equivalent to IV,” “superior absorption,” or “direct delivery into the bloodstream” should not be assumed without route-specific pharmacokinetic evidence.
Iontophoresis provides a plausible and established mechanism for enhancing transdermal movement of appropriate compounds. That is different from proving a particular systemic exposure or clinical outcome for NAD+.
NAD+ Delivery Methods Compared
There is no scientifically justified basis for declaring one NAD-related delivery method “best” for every patient. The available routes answer different questions and carry different levels and types of evidence.
| Delivery Approach | How It Differs | Major Evidence Consideration |
|---|---|---|
| Passive transdermal NAD+ patch | No electrical assistance; relies on passive movement through skin | Direct evidence of predictable systemic NAD+ delivery remains limited. |
| NAD+ iontophoresis patch | Uses low-level current to assist transport | Human use has been reported, but NAD-specific controlled evidence remains preliminary. |
| Oral NAD-related products | Taken through the gastrointestinal tract | Larger human research literature exists, particularly for NAD precursors; findings cannot automatically be generalized to NAD+ itself. |
| Injection | Parenteral administration without relying on skin penetration | Requires an injectable formulation and appropriate clinical oversight |
| IV administration | Delivers material directly into the circulation | Avoids intestinal and skin barriers, but route of administration alone does not establish clinical benefit. |
| NAD+ precursors | Supply compounds used in NAD metabolism rather than necessarily administering NAD+ itself. | Pharmacology differs by precursor, formulation, and dose. |
The practical conclusion is that delivery efficiency, biological effect, and demonstrated clinical benefit are three different questions.
Which Iontophoresis Patches Are Relevant to NAD+ Delivery?
We carry several wearable iontophoresis systems, but evidence involving one device should not automatically be transferred to another.
| Balego Product Family | Relevance to NAD+ Research | Important Distinction |
|---|---|---|
| IontoPatch STAT | The model reported in the 2024 human NAD+ study | A study using STAT does not establish the effectiveness of NAD+ generally. |
| IontoPatch 80 | Same broader IontoPatch family | Different electrical/wear profile; NAD+-specific clinical equivalence has not been established. |
| IontoPatch Extra Strength | Higher electrical-dose-capacity IontoPatch option | Should not be assumed equivalent to the research protocol |
| ACTIVApatch / IontoGo | Alternative self-contained iontophoresis systems | Different device design; no NAD+-specific clinical equivalence should be inferred. |
For current specifications, available models, and purchasing information, see our IontoPatch iontophoresis patches.
We also offer ACTIVApatch iontophoresis patches. Clinicians comparing the two platforms can use our detailed IontoPatch vs. ACTIVApatch comparison guide.
The iontophoresis devices linked above are sold without medication. The appropriate medication or ionic solution must be separately selected and supplied according to the applicable clinical and prescribing requirements.
Is IontoPatch FDA approved for NAD+?
IontoPatch has an FDA 510(k) clearance as an iontophoresis device. The FDA database identifies IontoPatch under the classification “Device, Iontophoresis, Other Uses.” The original 510(k) was determined substantially equivalent in 2000. (FDA Access Data)
That device clearance should not be interpreted as FDA approval of NAD+ for every iontophoresis application, a particular compounded NAD+ formulation, or a particular NAD+ treatment protocol.
In other words:
FDA clearance of an iontophoresis device and evidence supporting a particular drug or formulation are separate regulatory and clinical questions.
NAD+ Patch Safety and Clinical Oversight
Iontophoresis is generally designed to use low current levels, but skin reactions can occur. In the 2024 NAD+/LDN study, 25% of participants experienced mild, short-lived irritation associated with the patch.
Users should follow the directions supplied with the selected device and the instructions of the treating clinician. Significant burning, pain, unexpected irritation, or other concerning symptoms warrant removal of the device and appropriate clinical evaluation.
Before treatment, the clinician should confirm factors such as
- Correct medication or solution
- Intended concentration and volume
- Correct polarity
- Appropriate iontophoresis device
- Treatment site
- Skin condition
- Prescribed electrical dose and treatment duration
For device-specific preparation and placement, use our IontoPatch application guide.
For frequently asked questions about models, medication, wear time, and safety, see the IontoPatch FAQ.
Frequently Asked Questions About NAD+ Iontophoresis
Does an NAD+ iontophoresis patch work?
There is published human research showing that NAD+ has been administered with an iontophoresis patch. In a 2024 pilot study, participants receiving both NAD+ iontophoresis and low-dose naltrexone reported improvements in fatigue and quality-of-life measures.
Because the study had no final placebo/control arm and used two treatments simultaneously, it does not establish the effectiveness of NAD+ iontophoresis by itself. Larger controlled studies are needed.
Is an NAD+ iontophoresis patch the same as a passive NAD patch?
No.
A passive patch relies on diffusion through the skin. An iontophoresis patch uses a low-level electrical current to assist transport of suitable ionic substances. They should not be treated as equivalent delivery technologies.
Was IontoPatch STAT actually used in a human NAD+ study?
Yes.
The published 2024 pilot study reported weekly NAD+ administration using an IontoPatch STAT. The treatment was combined with daily low-dose naltrexone.
Does the study prove that 400 mg is the correct NAD+ iontophoresis dose?
No.
The publication describes a study protocol involving a 400 mg/mL solution and 1 mL application. A research protocol should not be converted into a general prescribing recommendation. Dose, formulation, treatment frequency, and administration should be determined by the appropriate healthcare professionals.
Which electrode should NAD+ be placed under?
Do not select polarity simply because the molecule is written as “NAD+.”
The relevant charge depends on the actual formulation and solution conditions. Clinicians should verify the prescribed formulation and pharmacy directions. See our NAD+ iontophoresis polarity guide for a more detailed discussion.
Is NAD+ iontophoresis better than IV NAD+?
There is not enough direct comparative evidence to make that conclusion.
IV administration places a substance directly into the circulation, whereas iontophoresis attempts to assist transport across intact skin. Demonstrating that two methods can deliver a substance does not establish equivalent pharmacokinetics or equivalent clinical outcomes.
Does FDA clearance of IontoPatch mean NAD+ is FDA approved for use with it?
No.
The device's FDA clearance and the regulatory status or clinical evidence for a particular medication, compounded preparation, or treatment protocol are separate matters.
Where can I compare iontophoresis patch systems?
Our Iontophoresis Collection includes wearable patches and other iontophoresis delivery options.
For a focused comparison of current wearable platforms, see IontoPatch vs. ACTIVApatch: Which Iontophoresis Patch Fits the Treatment?.
The Bottom Line on NAD+ Iontophoresis Patches
NAD+ iontophoresis is scientifically more specific than the broad marketing term “NAD patch.” Iontophoresis uses an established electrically assisted transdermal-delivery mechanism, and NAD+ has been administered with an IontoPatch STAT in published human research.
That does not yet mean that NAD+ iontophoresis has established systemic bioavailability, an optimized dose, superiority over other NAD-related delivery methods, or proven clinical effectiveness by itself.
For clinicians and informed consumers, the most defensible interpretation of the evidence is therefore
The delivery technology is established. NAD+-specific clinical evidence is emerging. The two should not be confused.
We offer iontophoresis patches and delivery systems for clinician-directed treatment workflows. Medication is not included with the linked patch systems, and any medication, compounded solution, or treatment protocol should be selected and supervised by appropriately qualified healthcare professionals.
Research References
Isman A, Nyquist A, Strecker B, et al. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain, Behavior, & Immunity – Health. 2024;36:100733.
Wang Y, Zeng L, Song W, Liu J. Influencing factors and drug application of iontophoresis in transdermal drug delivery: an overview of recent progress. Drug Delivery and Translational Research. 2022;12(1):15–26. (PubMed)
U.S. Food and Drug Administration. IontoPatch 510(k) Premarket Notification, K992708. View the FDA 510(k) record.
Medical disclaimer: This article is provided for educational and product-comparison purposes and is not a prescribing guide or a substitute for medical advice. Medication selection, dose, formulation, polarity, and treatment parameters should be determined by the appropriate licensed healthcare professional.
